Prevalence and Reversibility of Lung Hyperinflation in Asthma
NCT ID: NCT01573364
Last Updated: 2012-04-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
450 participants
OBSERVATIONAL
2011-02-28
2012-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Target Validation and Discovery in Idiopathic Bronchiectasis
NCT03750734
Management of Patients With Alpha-1 Antitrypsin Deficiency Associated Emphysema
NCT00700934
Change in Airway Peripheral Tone in COPD
NCT04166812
Development of Small Airway Disease Questionnaire
NCT01360294
Prognosis of Bronchiectasis in Children--A Multicenter Prospective Cohort Study
NCT02564731
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* the evaluation of the hyperinflation defined by an increase of the residual volume (RV),
* the observation of the relationship between the hyperinflation and the asthma characteristics,
* the study of the improvement of the functional parameters after a reversibility test
* the evaluation of the correlation between hyperinflation parameters evolution, chest tightness and dyspnea
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient requiring a check-up including a pulmonary function test by plethysmography with a reversibility test
Exclusion Criteria
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chiesi Farmaceutici S.p.A.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Capucine de Meynard, MD
Role: STUDY_DIRECTOR
Chiesi S.A.
Daniel Dusser, MD, Prof
Role: STUDY_CHAIR
Hopital Cochin Paris France
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Laboratoire Chiesi S.A.
Courbevoie, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Perez T, Chanez P, Dusser D, Devillier P. Prevalence and reversibility of lung hyperinflation in adult asthmatics with poorly controlled disease or significant dyspnea. Allergy. 2016 Jan;71(1):108-14. doi: 10.1111/all.12789. Epub 2015 Nov 6.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EQFST5213
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.